No more compounded Avastin

Why This Topic Matters

The article affects how eye-care practices manage drug sourcing, billing, and reimbursement for intravitreal therapy, especially when compounded Avastin is no longer available through prior channels. It is relevant to practices tracking Medicare billing, HCPCS updates, and treatment access for retinal disease.

Article Sections

1. Compounded Avastin access and ophthalmology billing concerns

   Discusses changes affecting access to Avastin for ocular use and the resulting implications for billing, drug sourcing, and practice operations. It also references related oversight and specialty-society response.

2. New J code for Lucentis

   Covers an expected HCPCS coding update for Lucentis and the timing of the new assignment. It notes that the article is addressing a pending reimbursement change rather than a full coding policy review.